NASDAQ:UMRX - Unum Therapeutics Stock Price, Forecast & News

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

Unum Therapeutics Inc (NASDAQ:UMRX) posted its earnings results on Tuesday, November, 12th. The company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.07. The firm earned $1.02 million during the quarter, compared to the consensus estimate of $4.41 million. Unum Therapeutics had a negative return on equity of 96.07% and a negative net margin of 388.07%. View Unum Therapeutics' Earnings History.

Unum Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Unum Therapeutics.

5 equities research analysts have issued 12-month price objectives for Unum Therapeutics' stock. Their forecasts range from $3.00 to $18.00. On average, they anticipate Unum Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,165.8% from the stock's current price. View Analyst Price Targets for Unum Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unum Therapeutics.

Media headlines about UMRX stock have been trending somewhat negative on Thursday, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Unum Therapeutics earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Unum Therapeutics.

Unum Therapeutics saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 372,700 shares, a drop of 18.6% from the December 31st total of 457,600 shares. Based on an average daily volume of 310,800 shares, the days-to-cover ratio is currently 1.2 days. Approximately 2.9% of the company's stock are sold short. View Unum Therapeutics' Current Options Chain.

Some companies that are related to Unum Therapeutics include Vaccinex (VCNX), TFF Pharmaceuticals (TFFP), Sunesis Pharmaceuticals (SNSS), Enlivex Therapeutics (ENLV), Sesen Bio (SESN), Oramed Pharmaceuticals (ORMP), VERONA PHARMA P/S (VRNA), Immunic (IMUX), Proteostasis Therapeutics (PTI), CV Sciences (CVSI), Synlogic (SYBX), Neos Therapeutics (NEOS), Oncolytics Biotech (ONCY), Catalyst Biosciences (CBIO) and Checkpoint Therapeutics (CKPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Unum Therapeutics investors own include SCYNEXIS (SCYX), AzurRx BioPharma (AZRX), Strongbridge Biopharma (SBBP), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Matinas BioPharma (MTNB), Acasti Pharma (ACST), KemPharm (KMPH), Vistagen Therapeutics (VTGN) and Genocea Biosciences (GNCA).

(UMRX) raised $75 million in an initial public offering on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

Unum Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.16%), Sectoral Asset Management Inc (0.48%), Acadian Asset Management LLC (0.40%) and Goldman Sachs Group Inc. (0.15%). Company insiders that own Unum Therapeutics stock include Liam Ratcliffe, Seth Ettenberg and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Unum Therapeutics.

UMRX stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc and Goldman Sachs Group Inc.. View Insider Buying and Selling for Unum Therapeutics.

UMRX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Acadian Asset Management LLC. Company insiders that have bought Unum Therapeutics stock in the last two years include Liam Ratcliffe and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Unum Therapeutics.

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of UMRX stock can currently be purchased for approximately $0.79.

Unum Therapeutics has a market capitalization of $24.22 million and generates $9.73 million in revenue each year. The company earns $-34,530,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Unum Therapeutics employs 56 workers across the globe.View Additional Information About Unum Therapeutics.

The official website for Unum Therapeutics is http://www.unumrx.com/.

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]